Home Tags ROR1

Tag: ROR1

FDA Approves Investigational New Drug of CS5001, a Potential Best-in-class ROR1-targeting...

The U.S. Food and Drug Administration (FDA) has authorized further development of CS5001, a potential global best-in-class antibody-drug conjugate (ADC) targeting receptor tyrosine kinase-like...

Merck Acquires VelosBio and Strengthens Oncology Pipeline with Investigational Antibody-Drug Conjugates

Merck & Co (MSD) has agreed to acquire VelosBio, a privately held clinical-stage biopharmaceutical company, for U.S. $ 2.75 billion in cash, subject to...

CStone Pharmaceuticals and LegoChem Biosciences Enter Global Licensing Agreement for...

Suzhou (China-) based CStone Pharmaceuticals and LegoChem Biosciences have signed a global licensing agreement in which CStone acquires exclusive rights for development and commercialization...

NBE-Therapeutics and Exelixis Sign Agreement to Advance Best-in-class ADCs Against Multiple...

Privately-owned Swiss biotech NBE-Therapeutics and Exelixis, confirmed a new partnership to discover and develop multiple antibody-drug conjugates (ADCs) for applications within oncology and hematology....

Boehringer Ingelheim Venture Fund and PPF Group Close a US $...

Privately-owned Swiss biotech company NBE-Therapeutics confirmed closing of a US $ 22M Series C financing round. The financing round was led by its existing...

WuXi Biologics and NBE-Therapeutics Collaborate in Development and Manufacturing Partnership

WuXi Biologics, an open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Swiss biotech NBE-Therapeutics, developing best-in-class, next-generation...

X